Welcome to our dedicated page for Tomi Environmental Solutions I news (Ticker: TOMZ), a resource for investors and traders seeking the latest updates and insights on Tomi Environmental Solutions I stock.
TOMI Environmental Solutions Inc. (NASDAQ: TOMZ) delivers cutting-edge decontamination systems through its patented SteraMist technology. This news hub provides investors and industry professionals with essential updates about the company’s infection prevention solutions, strategic partnerships, and regulatory milestones.
Access real-time announcements including product launches, financial results, and technology licensing agreements. Our curated collection features press releases about BIT platform advancements, facility deployments across healthcare and government sectors, and compliance achievements.
Key updates cover global expansion efforts, research collaborations with defense organizations, and industry certifications validating SteraMist’s efficacy. Bookmark this page to monitor how TOMI addresses evolving disinfection challenges while maintaining operational excellence in critical environments.
TOMI Environmental Solutions (NASDAQ:TOMZ), a global decontamination technology provider, reported Q2 2025 financial results showing mixed performance. Revenue declined to $1.03M from $3.01M in Q2 2024, while maintaining a strong gross margin of 66%. Service revenue grew 33% year-over-year to $378,000.
The company reported a net loss of $1.24M ($0.06 per share) compared to net income of $30,000 in Q2 2024. Notable highlights include a sales order backlog of $1.4M and combined recognized revenue, deferred revenue, and backlog of $4.6M. TOMI is pursuing approximately $15M in opportunities, with $7M designated as high priority.
The company completed a $435,000 convertible note financing and maintains working capital of $2.8M. Management is focused on expanding recurring service contracts, growing solution sales, and strengthening its corporate team.
TOMI Environmental Solutions (NASDAQ:TOMZ), a global decontamination and infection prevention company, has secured significant orders from a major eye health company. The customer placed orders for multiple Surface Units and disinfection carts for facilities in South Carolina and Florida, with expected total purchases of $385,000 for 2025.
The South Carolina facility has successfully completed validation testing, demonstrating SteraMist's effectiveness against Geobacillus stearothermophilus spores. The Florida facility is scheduled for qualification using the same methodology. This expansion validates TOMI's Binary Ionization Technology® (BIT™) platform, which uses ionized Hydrogen Peroxide (iHP™) technology for superior disinfection in regulated environments.
TOMI Environmental Solutions (NASDAQ: TOMZ), a global decontamination and infection prevention company, has scheduled its Q2 2025 earnings conference call for August 14, 2025, at 4:30 p.m. ET. The company will release its financial results for the quarter ended June 30, 2025, after market close on the same day.
TOMI specializes in disinfection solutions through its proprietary Binary Ionization Technology® (BIT™) platform, which was developed under a DARPA defense grant. The technology uses ionized Hydrogen Peroxide (iHP™) and serves various sectors including hospitals, biosafety labs, pharmaceutical facilities, and commercial buildings.
TOMI Environmental Solutions (NASDAQ:TOMZ), a global decontamination and infection prevention company, has secured its fourth order for the SteraMist Integration System (SIS) platform from ARES Distribution. The order, placed for a biomedical research university in Coral Gables, Florida, is scheduled for delivery in late 2025.
The company's proprietary Binary Ionization Technology® (BIT™), developed under a DARPA defense grant, uses ionized Hydrogen Peroxide (iHP™) technology for superior disinfection. The technology serves various sectors including hospitals, biosafety labs, pharmaceutical facilities, and commercial buildings.
TOMI Environmental Solutions (NASDAQ:TOMZ), a global decontamination solutions provider, has announced the successful first installation of its SteraMist Integration System – Standalone (SIS-SA) in the life sciences sector, specifically for the pharmaceutical isolator market. The installation was completed at a leading pharmaceutical CDMO that had previously invested in SteraMist technology.
The company expects to generate over $500,000 in revenue from the new SIS-SA product in fiscal 2025. With the life science sterility testing market projected to reach $3.4 billion by 2031 at a CAGR of 12.4%, TOMI is positioning itself to capitalize on the growing demand for sterile drug manufacturing environments through its innovative Binary Ionization Technology® (BIT™) platform.